|
Cuba and Brazil analyze results of
biopharmaceutical medicine
More than 100 Cuban and Brazilian experts will share
their experiences on
recombinant human erythropoietin, a highly effective
biotechnological medicine able to treat anemia
associated with different types of illnesses.
The Cuba-Brazil event, entitled:
Widespread use of
erythropoietin
in the National
Health System,
which will take place October 13-14 in the Havana
Convention Center, aims to promote scientific
exchanges on the clinical results and benefits of
the product, developed at the Molecular Immunology
Center (CIM), in Havana.
Made available for medical use 15 years ago the
medicine has benefited more than 250,000 people from
Cuba and other countries primarily in Latin and
Central America and the Caribbean, where the product
is exported, according to sources from the event
organizing committee.
The conference will also focus on debates concerning
results from clinical trails and product safety
analysis of one of the CIM’s leading products, which
has achieved results in 20 countries.
Recombinant human erythropoietin
forms part of the basic catalog of essential
medicines in Cuba and is available nationwide to all
dialysis, onco-hematology and neonatology services,
stated experts.
It has also shown positive results in treating
anemia in patients suffering from renal illnesses;
AIDS; cancer suffers undergoing chemotherapy and
premature anemia.
Founded by Fidel Castro on December 5, 1994, the CIM
works to obtain and produce new biopharmaceuticals
to treat cancer and other chronic non-transmittable
illnesses on the National Health System, conduct
scientific research, realize sustainable production
and contribute to the national economy.
|
